학술논문
730MO First-in-human phase I study of INCAGN02390, a TIM-3 monoclonal antibody antagonist in patients with advanced malignancies
Document Type
Abstract
Author
Source
In Annals of Oncology September 2022 33 Supplement 7:S876-S877
Subject
Language
ISSN
0923-7534